These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 31560295)
1. Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration. Frantellizzi V; Pontico M; Pani A; Pani R; De Vincentis G Curr Radiopharm; 2020; 13(2):159-163. PubMed ID: 31560295 [TBL] [Abstract][Full Text] [Related]
2. Radium Ra 223 dichloride in castration-resistant prostate cancer. Joung JY; Ha YS; Kim IY Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665 [TBL] [Abstract][Full Text] [Related]
4. Radium - 223 (Xofigo) for prostate cancer. Med Lett Drugs Ther; 2013 Sep; 55(1426):79-80. PubMed ID: 24081388 [No Abstract] [Full Text] [Related]
5. Standard Safety Procedure Before Therapeutic Administration of Marcondes Braga Ribeiro A; Nóbrega Pereira Lima E J Nucl Med Technol; 2024 Sep; 52(3):219-220. PubMed ID: 39237342 [No Abstract] [Full Text] [Related]
6. Practical guide to the use of radium 223 dichloride. Den RB; Doyle LA; Knudsen KE Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727 [TBL] [Abstract][Full Text] [Related]
7. Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data. Soldatos TG; Iakovou I; Sachpekidis C Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31100964 [No Abstract] [Full Text] [Related]
8. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979 [TBL] [Abstract][Full Text] [Related]
9. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Jadvar H; Challa S; Quinn DI; Conti PS Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408 [TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. McGann S; Horton ER Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268 [TBL] [Abstract][Full Text] [Related]
12. Dosing, administration, and safety of radium-223: How I do it. Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625 [TBL] [Abstract][Full Text] [Related]
13. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions. Nilsson S Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093 [TBL] [Abstract][Full Text] [Related]
14. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Nilsson S Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669 [TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038 [TBL] [Abstract][Full Text] [Related]
16. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma. Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613 [TBL] [Abstract][Full Text] [Related]